Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Muralikrishna, Yaragani"'
Autor:
Muralikrishna, Yaragani, Prasad, Yadlapalli, Sriram, Raghavan, Thota, Giridhar, Venkata Basaveswara Rao, Mandava, Ravindra Vikram, Singh, Rajasekhara Prasad, Kottapalli, Saravanan, Chinnusamy
Publikováno v:
Chemical Biology & Drug Design. 101:614-625
Because androgen receptor (AR) signalling is important for the development and progression of prostate cancer (PC), AR antagonists are utilized in clinical practices to treat PC and are referred to as androgen deprivation therapy (ADT). However, cont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d663b601de509aa8de8e5c5f2d37354
https://doi.org/10.1111/cbdd.14151
https://doi.org/10.1111/cbdd.14151
Autor:
Muralikrishna Yaragani, Venkata Basaveswara Rao Mandava, Sriram Raghavan, Prasad Yadlapalli, Giridhar Thota, Ravindra Vikram Singh, Chinnusamy Saravanan, Rajasekhara Prasad Kottapalli
Publikováno v:
ChemistrySelect. 6:8741-8745
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfc62378bc826043f661d279faa97671
https://doi.org/10.1002/slct.202101546
https://doi.org/10.1002/slct.202101546
Autor:
Venkata Basaveswara Rao Mandava, Muralikrishna Yaragani, Rajasekhara Prasad Kottapalli, Sriram Raghavan, Prasad Yadlapalli, Niraikulam Ayyadurai, Saravanan Chinnusamy
Publikováno v:
Journal of Chemical Sciences. 132
In order to improve the antiproliferative activity of androgen receptor (AR) antagonists, which used clinically for the treatment of prostate cancer that is a major cause of male death in worldwide, we report the design and synthesis of a series of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12463702beecd9de25ab517d4b7a8485
https://doi.org/10.1007/s12039-020-01833-x
https://doi.org/10.1007/s12039-020-01833-x